The Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) (ClinicalTrials.gov Identifier: NCT00492700) study [61] showed favorable effects of this agent on insulin sensitivity and ALT normalization and a significant 30% reduction in hepatic steatosis vs. placebo [61]. This evidence concerns the gene INS and fatty liver disease.